Jürgen Sonnemann1,2,3, Zhao-Qi Wang4,5, Christian Marx4, Marc U Schaarschmidt6,7, Joanna Kirkpatrick4,8, Lisa Marx-Blümel6,7, Melisa Halilovic4, Martin Westermann9, Doerte Hoelzer10,11, Felix B Meyer10, Yibo Geng4,12, Katrin Buder4, Hauke M Schadwinkel6,7, Kanstantsin Siniuk4, Sabine Becker6,7, René Thierbach10, James F Beck6. 1. Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany. juergen.sonnemann@med.uni-jena.de. 2. Research Center Lobeda, Jena University Hospital, Jena, Germany. juergen.sonnemann@med.uni-jena.de. 3. Klinik Für Kinder- Und Jugendmedizin, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. juergen.sonnemann@med.uni-jena.de. 4. Leibniz Institute On Aging - Fritz Lipmann Institute (FLI), Jena, Germany. 5. Faculty of Biology and Pharmacy, Friedrich Schiller University of Jena, Jena, Germany. 6. Department of Pediatric Hematology and Oncology, Children's Clinic, Jena University Hospital, Jena, Germany. 7. Research Center Lobeda, Jena University Hospital, Jena, Germany. 8. Francis Crick Institute, London, UK. 9. Electron Microscopy Center, Jena University Hospital, Jena, Germany. 10. Department of Human Nutrition, Institute of Nutrition, Friedrich Schiller University Jena, Jena, Germany. 11. Biopharmaceutical New Technologies (BioNTech) Corporation, Mainz, Germany. 12. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Abstract
INTRODUCTION: Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells. METHODS: Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution as well as fluorescence and transmission electron microscopy. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis. RESULTS: AUY922 alone induced DNA damage, apoptosis and ER stress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis, while p53 null cells accumulated higher levels of DNA damage, ER stress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect. CONCLUSION: Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.
INTRODUCTION:Ewing's sarcoma is an aggressive childhood malignancy whose outcome has not substantially improved over the last two decades. In this study, combination treatments of the HSP90 inhibitor AUY922 with either the ATR inhibitor VE821 or the ATM inhibitor KU55933 were investigated for their effectiveness in Ewing's sarcoma cells. METHODS: Effects were determined in p53 wild-type and p53 null Ewing's sarcoma cell lines by flow cytometric analyses of cell death, mitochondrial depolarization and cell-cycle distribution as well as fluorescence and transmission electron microscopy. They were molecularly characterized by gene and protein expression profiling, and by quantitative whole proteome analysis. RESULTS:AUY922 alone induced DNA damage, apoptosis and ERstress, while reducing the abundance of DNA repair proteins. The combination of AUY922 with VE821 led to strong apoptosis induction independent of the cellular p53 status, yet based on different molecular mechanisms. p53 wild-type cells activated pro-apoptotic gene transcription and underwent mitochondria-mediated apoptosis, while p53 null cells accumulated higher levels of DNA damage, ERstress and autophagy, eventually leading to apoptosis. Impaired PI3K/AKT/mTOR signaling further contributed to the antineoplastic combination effects of AUY922 and VE821. In contrast, the combination of AUY922 with KU55933 did not produce a cooperative effect. CONCLUSION: Our study reveals that HSP90 and ATR inhibitor combination treatment may be an effective therapeutic approach for Ewing's sarcoma irrespective of the p53 status.
Authors: Srikanth R Ambati; Eloisi Caldas Lopes; Kohji Kosugi; Ullas Mony; Ahmet Zehir; Smit K Shah; Tony Taldone; Andre L Moreira; Paul A Meyers; Gabriela Chiosis; Malcolm A S Moore Journal: Mol Oncol Date: 2013-12-15 Impact factor: 6.603
Authors: Brian D Crompton; Chip Stewart; Amaro Taylor-Weiner; Gabriela Alexe; Kyle C Kurek; Monica L Calicchio; Adam Kiezun; Scott L Carter; Sachet A Shukla; Swapnil S Mehta; Aaron R Thorner; Carmen de Torres; Cinzia Lavarino; Mariona Suñol; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Michael S Lawrence; Petar Stojanov; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Sara Seepo; Brendan Blumenstiel; Matthew DeFelice; Ivan Imaz-Rosshandler; Angela Schwarz-Cruz Y Celis; Miguel N Rivera; Carlos Rodriguez-Galindo; Mark D Fleming; Todd R Golub; Gad Getz; Jaume Mora; Kimberly Stegmaier Journal: Cancer Discov Date: 2014-09-03 Impact factor: 39.397
Authors: Thomas G P Grünewald; Florencia Cidre-Aranaz; Didier Surdez; Eleni M Tomazou; Enrique de Álava; Heinrich Kovar; Poul H Sorensen; Olivier Delattre; Uta Dirksen Journal: Nat Rev Dis Primers Date: 2018-07-05 Impact factor: 52.329
Authors: Franck Tirode; Didier Surdez; Xiaotu Ma; Matthew Parker; Marie Cécile Le Deley; Armita Bahrami; Zhaojie Zhang; Eve Lapouble; Sandrine Grossetête-Lalami; Michael Rusch; Stéphanie Reynaud; Thomas Rio-Frio; Erin Hedlund; Gang Wu; Xiang Chen; Gaelle Pierron; Odile Oberlin; Sakina Zaidi; Gordon Lemmon; Pankaj Gupta; Bhavin Vadodaria; John Easton; Marta Gut; Li Ding; Elaine R Mardis; Richard K Wilson; Sheila Shurtleff; Valérie Laurence; Jean Michon; Perrine Marec-Bérard; Ivo Gut; James Downing; Michael Dyer; Jinghui Zhang; Olivier Delattre Journal: Cancer Discov Date: 2014-09-15 Impact factor: 39.397
Authors: Jeffrey C Martin; Tamara J Hoegel; Miranda L Lynch; Anna Woloszynska; Thomas Melendy; Joyce E Ohm Journal: Mol Cancer Res Date: 2020-10-05 Impact factor: 6.333
Authors: Christine M Heske; Arnulfo Mendoza; Leah D Edessa; Joshua T Baumgart; Sunmin Lee; Jane Trepel; David A Proia; Len Neckers; Lee J Helman Journal: Oncotarget Date: 2016-10-04
Authors: Maria Nieto-Soler; Isabel Morgado-Palacin; Vanesa Lafarga; Emilio Lecona; Matilde Murga; Elsa Callen; Daniel Azorin; Javier Alonso; Andres J Lopez-Contreras; Andre Nussenzweig; Oscar Fernandez-Capetillo Journal: Oncotarget Date: 2016-09-13